<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="dangerous pandemic known as coronavirus disease 2019 (COVID-19). The SARS-CoV-2" exact="infection" post="has triggered an impressive amount of clinical and experimental"/>
 <result pre="therapeutic options but advises towards a more cautious and individualized" exact="treatment" post="approach centred on the clinical features, immune particularities, and"/>
 <result pre="an impressive armamentarium of molecules was proposed for the SARS-CoV-2" exact="treatment" post="in a very short period of time and the"/>
 <result pre="et al., 2020). Certain protease inhibitors frequently used in the" exact="treatment" post="of HIV such as lopinavir/ritonavir have already been tested"/>
 <result pre="infected cells to control the early stage of the viral" exact="infection" post="through the release of proinflammatory cytokines and Th1 immune"/>
 <result pre="the permission to access and use convalescent plasma for the" exact="treatment" post="of life-threatening SARS-CoV-2 infection. However, there is still, limited"/>
 <result pre="is still, limited data on the sero-conversion following the SARS-CoV-2" exact="infection" post="as well as on its associated side effects, such"/>
 <result pre="2020). The available therapeutic agents target the pathogenic steps of" exact="infection" post="(viral entry or post-entry steps) as well as the"/>
 <result pre="et al., 2020). Furthermore rhACE2 was also used in the" exact="treatment" post="of ARDS as an alternative to prevent both the"/>
 <result pre="Pharmacologic Molecules Chlorpromazine, a drug not yet used in the" exact="treatment" post="of coronaviruses despite experimental results (Yang and Shen, 2020)"/>
 <result pre="May a phase 3 of a clinical trial on the" exact="treatment" post="of symptomatic COVID-19 in combination with either Lopinavir/Ritonavir (NCT04320277)"/>
 <result pre="inhibitor is an immunomodulator currently approved by the FDA for" exact="treatment" post="of polycythemia vera is currently studied in a Phase"/>
 <result pre="is umifenovir (arbidol), a broad-spectrum antiviral agent used in the" exact="treatment" post="of COVID-19 patients across China, Russia, as well as"/>
 <result pre="mesylate, a protease inhibitor approved by the FDA in the" exact="treatment" post="of chronic pancreatitis can also block the cellular entry"/>
 <result pre="2020) or in monotherapy, as part of a 10-day intravenous" exact="treatment" post="in COVID-19 patients with severe pneumonia (Adaptive COVID-19 Treatment"/>
 <result pre="of remdesivir on a compassionate-use basis to patients with SARS-CoV-2" exact="infection" post="receiving oxygen support, has been associated with a clinical"/>
 <result pre="plays a protective role in the initial phase of the" exact="infection" post="but later contributes to the â€œcytokine stormâ€™â€™ either directly"/>
 <result pre="induction of other cytokines, as was proved during the MERS" exact="infection" post="(Channappanavar et al., 2019). Hence, IFN therapy could play"/>
 <result pre="database. Table 1 Interferon therapy in clinical evaluation in SARS-CoV-2" exact="infection" post="(July 20, 2020). Biological treatment Study identifier number, locations"/>
 <result pre="in clinical evaluation in SARS-CoV-2 infection (July 20, 2020). Biological" exact="treatment" post="Study identifier number, locations IFN-beta, cholchicine, rivaroxaban, aspirin NCT04331899,"/>
 <result pre="humanized IgG1 anti IL-6 receptor mAb commonly used in the" exact="treatment" post="of rheumatoid arthritis and also approved in the treatment"/>
 <result pre="the treatment of rheumatoid arthritis and also approved in the" exact="treatment" post="of cytokine release syndrome. Tocilizumab has already reached multiple"/>
 <result pre="(GM-CSF) is the most recent monoclonal antibody proposed for the" exact="treatment" post="of COVID-19 and will be assessed through the US"/>
 <result pre="reported a positive effect of intravenous dexamethasone administration in the" exact="treatment" post="of COVID-19. The study showed that a 10-day treatment"/>
 <result pre="the treatment of COVID-19. The study showed that a 10-day" exact="treatment" post="with low doses of dexamethasone (6 mg/day) reduced the"/>
 <result pre="oxygen. This observation additionally highlights the need to adapt the" exact="treatment" post="to the dynamic nature of COVID-19 and to adopt"/>
 <result pre="MSC. Table 2 Cellular therapies in clinical evaluation in SARS-Cov2" exact="infection" post="(July 20, 2020). Biological product Study identifier number, country"/>
 <result pre="through compassionate care programmes and as of April 2020, this" exact="treatment" post="is considered an â€œemergency investigational new drugâ€� authorized by"/>
 <result pre="this therapy (Bloch et al., 2020). Side effects of this" exact="treatment" post="could exclude critical patients from the clinical trials (Li"/>
 <result pre="the types of vaccines against COVID-19 which have passed preclinical" exact="testing" post="and have entered the clinical setting: Vector-Based Vaccines induce"/>
 <result pre="non-specific vaccine which has received most attention in the SARS-CoV-2" exact="infection" post="due to its ability to boost the immunity against"/>
 <result pre="the disease could be devastating in another. Hence, the best" exact="treatment" post="option appears to be a molecule which would restrict"/>
 <result pre="production of a vaccine, while on the short-term the best" exact="treatment" post="option requires further in-depth studies on the cellular invasion"/>
 <result pre="stepping stone for the handling of future epidemics. The SARS-CoV-2" exact="infection" post="proved once again that viruses leave a very short"/>
 <result pre="al. (2020). Deployment of convalescent plasma for the prevention and" exact="treatment" post="of COVID-19. J. Clin. Invest.130 (6), 2757â€&quot;2765. 10.1172/JCI13874532254064 BollesM.DemingD.LongK.AgnihothramS.WhitmoreA.FerrisM.et"/>
 <result pre="IFN-I response timing relative to virus replication determines MERS coronavirus" exact="infection" post="outcomes. J. Clin. Invest.129 (9), 3625â€&quot;3639. 10.1172/JCI12636331355779 ChenX.ZhaoB.QuY.ChenY.XiongJ.FengY.et al."/>
 <result pre="Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV)" exact="infection" post="in senescent BALB/c mice: CD4+ T cells are important"/>
 <result pre="10.1016/J.IJANTIMICAG.2020.106023 GautretP.LagierJ.-C.ParolaP.HoangV. T.MeddebL.MailheM.et al. (2020). Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trial."/>
 <result pre="Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the" exact="treatment" post="of patients admitted to hospital with COVID-19: an open-label,"/>
 <result pre="infection. CMAJ192 (17), E4540â€&quot;E453. 10.1503/cmaj.200528 KawaseM.ShiratoK.van der HoekL.TaguchiF.MatsuyamaS. (2012). Simultaneous" exact="treatment" post="of human bronchial epithelial cells with serine and cysteine"/>
 <result pre="Virol.86 (12), 6537â€&quot;6545. 10.1128/JVI.00094-1222496216 KewanT.CovutF.Alâ€&quot;JaghbeerM. J.RoseL.GopalakrishnaK. V.AkbikB. (2020). Tocilizumab for" exact="treatment" post="of patients with severe COVIDâ€&quot;19: A retrospective cohort study."/>
 <result pre="care unit patients. Transfusion51 (2), 338. 10.1111/j.1537-2995.2010.02816.x20723173 LianN.XieH.LinS.HuangJ.ZhaoJ.LinQ. (2020). Umifenovir" exact="treatment" post="is not associated with improved outcomes in patients with"/>
 <result pre="(25), 2441â€&quot;2448. Â 10.1056/NEJMoa200897532356628 RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.et al. (2020). Baricitinib as potential" exact="treatment" post="for 2019-nCoV acute respiratory disease. Lancet (London England)395 (10223),"/>
 <result pre="299â€&quot;311. 10.1016/j.ccc.2017.12.00529482908 SallardE.LescureF.-X.YazdanpanahY.MentreF.Peiffer-SmadjaN. (2020). Type 1 interferons as a potential" exact="treatment" post="against COVID-19. Antiviral Res.178, 104791. 10.1016/j.antiviral.2020.10479132275914 SavarinoA.BoelaertJ. R.CassoneA.MajoriG.CaudaR. (2003)."/>
 <result pre="in posterior oropharyngeal saliva samples and serum antibody responses during" exact="infection" post="by SARS-CoV-2: an observational cohort study. Lancet Infect. Dis.20"/>
 <result pre="al. (2005). Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread. Virol. J.2 (1), 69. 10.1186/1743-422X-2-6916115318 VossA. (2020)."/>
 <result pre="cohort and their implications. medRxiv2020.03.30.20047365. 10.1101/2020.03.30.20047365 XuX.HanM.LiT.SunW.WangD.FuB.et al. (2020). Effective" exact="treatment" post="of severe COVID-19 patients with tocilizumab. Proc. Natl. Acad."/>
 <result pre="108517. 10.1016/j.clim.2020.10851732585295 YouyaoX. U.Yizhen ChenX. T. (2020). Guidelines for the" exact="diagnosis" post="and treatment of coronavirus disease 2019 (COVID-19) in China."/>
 <result pre="YouyaoX. U.Yizhen ChenX. T. (2020). Guidelines for the diagnosis and" exact="treatment" post="of coronavirus disease 2019 (COVID-19) in China. Glob. Heal."/>
</results>
